Proove Biosciences has Presented at the American Academy of Addiction Psychiatry

Share Article

Mary Knauer MBA; PhD of Proove Biosciences presented an Observational Study to Calculate Addictive Risk to Opioids Due to Genetic Predisposition in Pain in Pain Patients (O.S.C.A.R. Study).

Doctors are in a unique position regarding prescription opioids and their potential abuse or misuse. Genetic testing can provide objective data to assist in treating patients for pain.

Proove Biosciences, a commercial and research leader in Personalized Medicine, presented research conducted through their O.S.C.A.R. study.

The Annual American Academy of Addiction Psychiatry Conference presents the most current and cutting-edge scientific developments in Addiction Psychiatry.

“Doctors are in a unique position regarding prescription opioids and their potential abuse or misuse,” said Mary Knauer. “Genetic testing can provide objective data to assist in treating patients for pain.”

Genetic susceptibility is generally known to be an important factor in understanding the problem of prescription opioid pain medication abuse. In practice however, this is not given the importance it deserves and not usually evaluated by clinicians before commencement of opioid prescription regime.

The O.S.C.A.R. study suggests that by using an Opioid Risk Index (ORI) score (formerly Narcotic Risk Index, NRI), physicians may be better able to determine which patients are at higher risk for prescription opioid medication misuse/abuse by genetic disposition. Due to current trial methods used to prescribe opioid medications to chronic pain patients, some patients may become addicted. Opioid addiction is becoming a much more important factor for clinicians to consider in developing a treatment plan for chronic pain.

About Proove Biosciences
Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We envision a future where physicians will know how patients are likely to respond to medications before writing a prescription. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Keira Dazi
Proove Biosciences
+1 855-776-6832 Ext: 1594
Email >
@proovebio
Follow >
Proove Biosciences, Inc.
since: 01/2012
Like >
Visit website